Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women

Hypertension

Volumn 33, Issue 5, 1999, Pages 1190-1194

  Seely, Ellen W ^a,b   Walsh, Brian W ^b   Gerhard, Marie D ^a   Williams, Gordon H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood pressure monitoring, ambulatory; Hypertension; Renin angiotensin system; Women

Indexed keywords

ESTRADIOL; PROGESTERONE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INTRAVAGINAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032922128     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.5.1190     Document Type: Article

References (26)

1. Gorton T. Blood pressure of adults by age and sex: United States 1960-1962. Vital Health Stat 1. 1964;11:1-40.
2. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol. 1990;75(4 suppl):18S-25S.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75: 1102-9.
4. Jaffe LS, Seely EW. The heterogeneity of the blood pressure response to hormonal contraceptives. Curr Opin Endocrinol Diabetes. 1995;2:257-265.
5. Woods JW. Oral contraceptives and hypertension. Lancet. 1976;2: 653-654.
6. Weir RJ, Briggs E, Mack A, Naismith L, Taylor L, Wilson E. Blood pressure in women taking oral contraceptives. BMJ. 1974;1:533-535.
7. Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation. 1987;76:753-758.
8. Jespersen CM, Arnung K, Hagen C, Hilden T, Nielsen F, Nielsen MD, Giese J. Effects of natural oestrogen therapy on blood pressure and renin-angiotensin system in normotensive and hypertensive menopausal women. J Hypertens. 1983;1:361-364.
9. Roseff SJ, Bangah ML, Kettel LM, Vale W, Rivier J, Burger HG, Yen SS. Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle. J Clin Endocrinol Metab. 1989; 69:1033-1039.
10. Rizzoni D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti-Rosei E. Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens. 1992; 5:180-186.
11. Palatini P, Penzo M, Racioppa A, Zugno E, Guzzardi G, Anaclerio M, Pessina AC. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med. 1992;152: 1855-1860.
12. Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C, Porcellati C. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation. 1993;88: 986-992.
13. Akkad AA, Halligan AWF, Abrams K, Al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynaecol. 1997;89: 97-103.
14. Mercuro G, Zoncu S, Pilia I, Lao A, Melis GB, Cherchi A. Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am J Cardiol. 1997;80:652-655.
15. van Ittersum FJ, van Baal WM, Kenemans P, Mijatovic V, Donker AJM, van der Mooren MJ, Stehouwer CDA. Ambulatory - not office - blood pressures decline during hormone replacement therapy in healthy post-menopausal women. Am J Hypertens. 1998;11:1147-1152.
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestogen regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
17. Wren BG, Routledge DA. Blood pressure changes: oestrogens in climacteric women. Med J Aust. 1981;2:528-531.
18. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280: 605-618.
19. Crane MG, Harris JJ. Plasma renin activity and aldosterone excretion rate in normal subjects: effect of ethinyl estradiol and medroxyprogesterone acetate. J Clin Endocrinol Metab. 1969;29:550-557.
20. Oelkers W, Blumel A, Schoneshofer M, Schwartz U, Hammerstein J. Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. J Clin Endocrinol Metab. 1976;43:1036-1040.
21. De Lignieres B, Basedevant A, Thomas G, Thalabard J-C, Mercier-Bodard C, Conard J, Guyene T-T, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R. Biological effects of estradiol-17 B in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab. 1986;62:536-541.
22. Schunkert H, Jan Danser AH, Hense H-W, Derkx FHM, Kurzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation. 1991;95: 39-45.
23. Feldmer M, Kalling M, Takahashi S, Mullins JJ, Ganten D. Glucocorticoid- and estrogen-responsive elements in the 5′-flanking region of the rat angiotensinogen gene. J Hypertens. 1991;9:1005-1012.
24. Clauser E, Gaillard I, Wei L, Corvol P. Regulation of angiotensinogen gene. Am J Hypertens. 1989;2:403-410.
25. Fukamizu A, Nishi K, Cho T, Saitoh M, Nakayama K, Ohkubo H, Nakanishi S, Murakami K. Structure of the rat renin gene. J Mol Biol. 1988;201:443-450.
26. Horiuchi M, Nakamura N, Tang SS, Barrett G, Dzau VJ. Molecular mechanism of tissue-specific regulation of mouse renin gene expression by cAMP. J Biol Chem. 1991;266:16247-16254.